Abstract Objective To compare the real‐world effectiveness and tolerability of calcitonin gene‐related peptide (CGRP) monoclonal antibodies (mAbs) and onabotulinumtoxinA in chronic migraine (CM) patients. Methods This multicenter study involved retrospective analysis of prospectively collected data of CM patients treated with CGRP mAbs or onabotulinumtoxinA, including difficult‐to‐treat (DTT) patients (i.e., ≥3 preventive failures). Treatment outcomes were determined at 6 months based on prospective headache diaries and Migraine Disability Assessment (MIDAS). Results The study included 316 (55 M/261F, mean age 44.4 ± 13.5 years) and 333 (61 M/272F, mean age 47.9 ± 13.4 years) CM patients treated with CGRP mAbs or onabotulinbumtoxinA, respectively. At 6 months, CGRP mAb treatment was associated with a greater decrease in monthly migraine days (MMDs) (−13.0 vs. −8.7 days/month, p &lt; 0.001) and a higher ≥50% responder rate (RR) (74.7% vs. 50.7%, p &lt; 0.001) compared with onabotulinumtoxinA injections. The findings were consistent in DTT patients (−13.0 vs. −9.1 MMDs, p &lt; 0.001; ≥50% RR: 73.9% vs. 50.3%, p &lt; 0.001) or those with medication‐overuse headache (MOH) (−13.3 vs. −9.0 MMDs, p &lt; 0.001; ≥50% RR: 79.0% vs. 51.6%, p &lt; 0.001). Besides, patients receiving CGRP mAbs had greater improvement (−42.2 vs. −11.8, p &lt; 0.001) and a higher ≥50% RR (62.0% vs. 40.0%, p = 0.001) in MIDAS scores and a lower rate of adverse events (AEs) (6.0% vs. 21.0%, p &lt; 0.001). However, none of the patients discontinued treatment due to AEs. Conclusions In this multicenter, real‐world study, CGRP mAbs were more effective than onabotulinumtoxinA in CM patients, even in DTT or MOH patients. All of these injectables were well tolerated. Further prospective studies are needed to verify these findings.

Comparative effectiveness and tolerability of calcitonin gene‐related peptide (<scp>CGRP)</scp> monoclonal antibodies and <scp>onabotulinumtoxinA</scp> in chronic migraine: A multicenter, real‐world study in Taiwan

Comparative effectiveness and tolerability of calcitonin gene‐related peptide (CGRP) monoclonal antibodies and onabotulinumtoxinA in chronic migraine: A multicenter, real‐world study in Taiwan